7-bromo-5-phenyl-1,2-dihydro-2h-1,4-benzodiazepin-2-one profile

7-bromo-5-phenyl-1,2-dihydro-2H-1,4-benzodiazepin-2-one: RN given refers to unlabeled parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	76167
CHEMBL ID	327679
SCHEMBL ID	1421181
MeSH ID	M0146806

Synonym
2894-61-3
CHEMBL327679
unii-b5o0sguu77
2h-1,4-benzodiazepin-2-one, 7-bromo-1,3-dihydro-5-phenyl-
b5o0sguu77 ,
7-bromo-5-phenyl-1,2-dihydro-2h-1,4-benzodiazepin-2-one
7-bpdbd
7-bromo-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one
CHEMDIVAM_000745
OPREA1_725240
smr000515772
MLS001208202
CHEMDIV1_020739
OPREA1_527217
7-bromo-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one
STK387438
7-bromo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
AKOS000678776
HMS645O15
STK854108
7-bromo-5-phenyl-3h-1,4-benzodiazepin-2-ol
NCGC00245210-01
AKOS005630842
HMS2827H16
F0133-0016
7-bromo-5-phenyl-1h-benzo[e][1,4]diazepin-2(3h)-one
AB00091651-01
SCHEMBL1421181
7-bromo-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one #
7-bromo-2,3-dihydro-5-phenyl-1h-1,4-benzodiazepin-2-one
ATCCWKYKHCKDGT-UHFFFAOYSA-N
DTXSID10183136
7-bromo-5-phenyl-1,3-dihydro-2h-benzo[e][1,4]diazepin-2-one
F1597-0044
Z57156344
bd-3
7-bromo-5-phenyl-1,2-di-hydro-3h-1,4-benzodiazepine-2-one
CAA89461
7-bromo-5-phenyl-2,3-dihydro-1h-1,4-benzodiazepin-2-one
EN300-235820

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	5.6234	0.0447	17.8581	100.0000	AID485294
TDP1 protein	Homo sapiens (human)	Potency	23.1093	0.0008	11.3822	44.6684	AID686978
Glycoprotein hormones alpha chain	Homo sapiens (human)	Potency	3.9811	4.4668	8.3448	10.0000	AID624291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
glycogen synthase kinase-3 alpha	Homo sapiens (human)	AC50	34.1800	0.0135	29.7434	171.7000	AID463203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
G protein-coupled receptor signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell population proliferation	Glycoprotein hormones alpha chain	Homo sapiens (human)
hormone-mediated signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
regulation of signaling receptor activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of steroid biosynthetic process	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell migration	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid gland development	Glycoprotein hormones alpha chain	Homo sapiens (human)
luteinizing hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycoprotein hormones alpha chain	Homo sapiens (human)
negative regulation of organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid hormone generation	Glycoprotein hormones alpha chain	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
protein binding	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
Golgi lumen	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
pituitary gonadotropin complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID13307	-Log C was determined by performing the maximum electroshock test	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID1150165	Muscle relaxant activity in cat suspended by scruff of neck assessed as relaxation of body and hind legs	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID1150161	Sedative activity in mouse	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID227697	Compound was evaluated for the Anti-fighting behavior.	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Neural networks applied to quantitative structure-activity relationship analysis.
AID13306	-Log C was determined by performing the incl screen test	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID228469	Evaluation of inclined screen test.	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Neural networks applied to quantitative structure-activity relationship analysis.
AID13304	-Log C was determined by performing the electroshock minimum test	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID1150162	Muscle relaxant activity in mouse	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID13308	-Log C was determined by performing the pentylenetetrazole test	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID13305	-Log C was determined by performing the foot shock test	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID1150164	Anticonvulsion activity in mouse assessed as protection against pentylenetetrazole-induced convulsion	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID1150163	Taming activity in mouse assessed as suppression of electrical current-induced aggressive behavior by foot-shock test	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID227698	Evaluation for the Anti-pentylenetetrazole effect.	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Neural networks applied to quantitative structure-activity relationship analysis.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (20.00)	18.7374
1990's	2 (20.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	4 (40.00)	24.3611
2020's	1 (10.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (8.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (91.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
ro 5-4864 4'-chlorodiazepam: selectively binds peripheral benzodiazepine receptor	1.95	1
carbazilquinone Carbazilquinone: An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.	3.07	1	organic molecular entity
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	1.95	1	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	3.46	2	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
nordazepam Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.	3.75	3	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	3.75	3	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
fludiazepam fludiazepam: RN given refers to parent cpd; structure	3.46	2	1,4-benzodiazepinone; organochlorine compound; organofluorine compound	anxiolytic drug
flunitrazepam Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.	3.75	3	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
flurazepam Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.	3.07	1	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; tertiary amino compound	anticonvulsant; anxiolytic drug; GABAA receptor agonist; sedative
nimetazepam nimetazepam : A nitrazepam which is substituted at positions 1 by a methyl group. It is used as an anticonvulsant and as a hypnotic for the short-term management of insomnia.	3.75	3	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; GABA modulator; sedative
nitrazepam Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).	3.75	3	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
cm 7116 norflutoprazepam: structure	3.75	3	benzodiazepine
prazepam Prazepam: A benzodiazepine that is used in the treatment of ANXIETY DISORDERS.	3.07	1	benzodiazepine
triaziquone Triaziquone: Alkylating antineoplastic agent used mainly for ovarian tumors. It is toxic to skin, gastrointestinal tract, bone marrow and kidneys.. triaziquone : A member of the class of 1,4-benzoquinones that is 1,4-benzoquinone in which three of the ring hydrogens are replaced by aziridin-1-yl groups.	3.07	1	1,4-benzoquinones; aziridines	alkylating agent; antineoplastic agent
chlordesmethyldiazepam [no description available]	3.75	3	benzodiazepine
n-desmethylflunitrazepam [no description available]	3.75	3
2-chlorodiazepam [no description available]	3.75	3
gidazepam gidazepam: prodrug for 7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepine-2-one	1.98	1
2,5-dimethyl-3,6-diaziridinyl-1,4-benzoquinone 2,5-dimethyl-3,6-diaziridinyl-1,4-benzoquinone: structure given in first source	3.07	1
ro 5-3438 Ro 5-3438: structure	3.46	2
n-desmethylflunitrazepam N-desmethylflunitrazepam: metabolite of flunitrazepam	3.75	3
ro 05-4082 ID 690: methyl deriv of clonazepam; structure	3.46	2
7-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one [no description available]	2.36	2	benzodiazepine

Condition	Relationship Strength	Studies
Absence Seizure [description not available]	1.95	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	1.95	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1

7-bromo-5-phenyl-1,2-dihydro-2h-1,4-benzodiazepin-2-one

Description

Cross-References

Synonyms (40)

Research Excerpts

Protein Targets (4)

Potency Measurements

Other Measurements

Biological Processes (14)

Molecular Functions (3)

Ceullar Components (5)

Bioassays (26)

Research

Studies (10)

Market Indicators

Research Demand Index: 11.92

Study Types

7-bromo-5-phenyl-1,2-dihydro-2h-1,4-benzodiazepin-2-one

Description

Cross-References

Synonyms (40)

Research Excerpts

Protein Targets (4)

Potency Measurements

Other Measurements

Biological Processes (14)

Molecular Functions (3)

Ceullar Components (5)

Bioassays (26)

Research

Studies (10)

Market Indicators

Research Demand Index: 11.92

Study Types

Related Drugs (23)

Related Conditions (6)